Puma Biotechnology Inc. announced that the U.S. Food and Drug Administration approved a labeling supplement for Nerlynx (neratinib) for the extended adjuvant treatment of HER2-positive early stage breast cancer.

The U.S. Food and Drug Administration approved Roche’s Kadcyla (trastuzumab emtansine) for adjuvant treatment of people with HER2-positive early breast cancer who have residual invasive disease after neoadjuvant taxane and Herceptin (trastuzumab)-based treatment.

Roche aims to broaden the use of the Swiss drugmaker’s Kadcyla breast cancer treatment as rivals crowd into the market with biosimilar copies of the company’s older mainstay product Herceptin.

Switzerland-based Roche announced a strong second quarterly report with a 7 percent increase in group sales for the first half of 2018 and a 20 percent increase in its core EPS.